Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

GSK presents positive registrational data to potentially expand Jideytro (zidesamtinib) to first ...

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at gsk.com →

◆ Verified

Fusion42 · 15 September 2026 · Fusion42 review

GSK reported positive data from the ARROS-1 trial showing high response rates and brain metastases clearance for Jideytro (zidesamtinib) in first-line treatment of ROS1-positive non-small cell lung cancer, supporting a planned FDA submission in 2026.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can pursue market entry in first-line ROS1-positive lung cancer if FDA approval hits, bypassing current treatment limits and expanding patient reach for targeted therapy.

◆ Coverage

1 source · 14 Sep 2026

◆ Related on Wire

◆ Topics

Biotechros1-nsclconcologydrug-approvalclinical-trialfda-submission